Cabio Biotech Wuhan Co Ltd (688089) — Cash Flow-to-Debt Ratio
Cabio Biotech Wuhan Co Ltd (688089) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of CN¥56.10 Million could theoretically repay 0% of its total liabilities (CN¥183.42 Million) in one year. See free cash flow generation of Cabio Biotech Wuhan Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cabio Biotech Wuhan Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cabio Biotech Wuhan Co Ltd across 12 annual periods. Also explore 688089 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cabio Biotech Wuhan Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Cabio Biotech Wuhan Co Ltd. For market capitalisation and broader financial context, see market cap of Cabio Biotech Wuhan Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.48x | CN¥173.04 Million | CN¥117.27 Million | ▲ +151.9% |
| 2023 | 0.59x | CN¥68.89 Million | CN¥117.60 Million | ▼ -38.3% |
| 2022 | 0.95x | CN¥176.40 Million | CN¥185.77 Million | ▼ -38.7% |
| 2021 | 1.55x | CN¥103.29 Million | CN¥66.68 Million | ▼ -37.0% |
| 2020 | 2.46x | CN¥145.88 Million | CN¥59.30 Million | ▼ -10.0% |
| 2019 | 2.73x | CN¥131.95 Million | CN¥48.26 Million | ▲ +41.6% |
| 2018 | 1.93x | CN¥106.16 Million | CN¥54.99 Million | ▼ -19.5% |
| 2017 | 2.40x | CN¥100.66 Million | CN¥41.98 Million | ▲ +184.5% |
| 2016 | 0.84x | CN¥62.53 Million | CN¥74.17 Million | ▲ +61.9% |
| 2015 | 0.52x | CN¥44.58 Million | CN¥85.60 Million | ▼ -53.3% |
| 2014 | 1.12x | CN¥46.34 Million | CN¥41.52 Million | ▲ +12.2% |
| 2013 | 0.99x | CN¥39.48 Million | CN¥39.68 Million | — |